December 08, 2013

Boehringer Ingelheim Announces Equine Research Award Recipients

Five researchers will study equine infectious diseases in 2014

Boehringer Ingelheim Vetmedica, Inc. (BIVI), has selected five equine researchers as recipients of its 2013 Advancement of Equine Research Awards.

Each researcher will receive a grant of $15,000 to study the diagnosis, pathogenesis, transmission, control and/or prevention of equine infectious diseases during 2014. An independent panel of equine practitioners, university professors and veterinary medicine researchers selected the recipients from among numerous proposals. The awards were announced at the recent American Association of Equine Practitioners Annual Convention in Nashville, Tenn.

“Infectious diseases are an ongoing challenge for equine practitioners and horse owners, which is why they have always been a high priority for our company,” says Steve Grubbs, DVM, PhD, DACVIM, equine technical manager, BIVI. “Along with our review board, I am impressed by both the quality of this year’s proposals and the innovative approaches to the problem. We look forward to working with these outstanding researchers to find practical solutions that ultimately can improve the quality of life for horses.”

The following researchers received awards:

  • Noah Cohen, VMD, MPH, PhD, DACVIM, professor at Texas A&M University, for “Is Diversity of the fecal microbiome associated with risk of Rhodoccocus equi foal pneumonia?”.
  • Nicola Pusterla, DVM, PhD, DACVIM, professor at the University of California, Davis, for “Investigation of the presence of novel viruses in nasal secretions of horses with infectious upper respiratory tract disease”.

  • David Horohov, PhD, professor at the University of Kentucky, for “Subisotypic differences in the immunoglobulin G response to Lawsonia intracellularis in vaccinated, seropositive and clinically affected horses”.
  • Ramiro E. Toribio, DVM, PhD, DACVIM, associate professor at The Ohio State University, for “Dynamics of the equine fecal microbiome in response to antibiotics”.

  • Ashely G. Boye, DVM, DACVIM, assistant professor of medicine at the University of Pennsylvania, for “Determining optimal sampling site for strangles carriers using loop-mediated isothermal (LAMP) PCR”.

“We are excited about the diversity of this year’s research topics,” Grubbs says. “Infectious diseases are complex problems that require an integrated approach that includes everything from prevention to proper diagnosis to timely vaccinations. I look forward to following the results of these studies as they contribute to future improvements in infectious disease management.”

The topic for the 2014 awards will be announced next spring. Veterinarians, diagnosticians and public and private researchers in the United States and Canada are eligible to submit proposals. Awards will be selected based on established criteria, including potential impact on the equine industry; originality and scientific quality; and probability of success in completing the yearlong studies.

For more information and complete submission instructions, please visit www.equinediseaseresearch.com.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.boehringer-ingelheim.com

Reference

1. Data on file at Boehringer Ingelheim Vetmedica, Inc.

Media Contact

Rene Ward

Director, U.S. Animal Health Communications
3902 Gene Field Road
St. Joseph, Missouri 64506